Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: Systematic review and meta-analysis

BMJ (Online)

Volumn 360, Issue , 2018, Pages

  Tainio, Karoliina ^a   Athanasiou, Antonios ^b   Tikkinen, Kari A O ^a   Aaltonen, Riikka ^c   Cárdenas, Jovita ⁱ   Hernandes ^d   Glazer Livson, Sivan ^a   Jakobsson, Maija ^a   Joronen, Kirsi ^c   Kiviharju, Mari ^a   Louvanto, Karolina ^a,e   Oksjoki, Sanna ^c   Tähtinen, Riikka ^f   Virtanen, Seppo ^a   Nieminen, Pekka ^a   Kyrgiou, Maria ^g,h   Kalliala, Ilkka ^a,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY OF TURKU   (Finland)

^d National Center for Health Technology Excellence (CENETEC)   (Mexico)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; AGE DISTRIBUTION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CERVICAL GLANDULAR INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CONSERVATIVE TREATMENT; DETERIORATION; DISEASE COURSE; EVIDENCE BASED MEDICINE; FOLLOW UP; HIGH RISK HUMAN PAPILLOMAVIRUS; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; META ANALYSIS; PATIENT ATTITUDE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TUMOR INVASION; UTERINE CERVIX ADENOCARCINOMA IN SITU; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS IDENTIFICATION; WART VIRUS; DISEASE EXACERBATION; FEMALE; PATHOLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CONSERVATIVE TREATMENT; DISEASE PROGRESSION; FEMALE; HUMANS; NEOPLASM GRADING;

EID: 85042707621     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k499     Document Type: Review

References (78)

1. IARC. IARC handbooks of cancer prevention: cervix cancer screening. Vol 10. IARC Press, 2005: 302.
2. Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer 2016;115:1140-6. 10.1038/bjc.2016.290
3. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004;191:105-13. 10.1016/j.ajog.2004.01.043
4. Massad LS, Einstein MH, Huh WK, et al, 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121:829-46. 10.1097/ AOG.0b013e3182883a34
5. Cytological changes in the cervix, vagina and vulva (online). Helsinki: Finnish Medical Society Duodecim, 2016. www.kaypahoito.fi. Accessed 21/11, 2016.
6. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116:1373-80. 10.1097/ AOG.0b013e3181fe777f
7. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasiagrade 2. Obstet Gynecol 2009;113:18-25. 10.1097/ AOG.0b013e31818f5008
8. Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92. 10.1097/00004347-199304000-00018
9. WHO Classification of Tumours of Female Reproductive Organs. Lyon: International Agency for Research on Cancer 2014.
10. Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 2005;331:1183-5. 10.1136/ bmj.38663.459039.7C
11. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-98. 10.1016/S0140-6736(06)68181-6
12. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284. 10.1136/bmj.a1284
13. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ 2014;349:g6192. 10.1136/bmj.g6192
14. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2015;9:CD008478.
15. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016;354:i3633. 10.1136/bmj.i3633
16. Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev 2017;11:CD012847.
17. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu 1973;8:301-28.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535. 10.1136/bmj.b2535
19. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 2014;72:39. 10.1186/2049-3258-72-39
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. 10.1136/bmj.327.7414.557
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315:629-34. 10.1136/bmj.315.7109.629
22. Alvarez RD, Conner MG, Weiss H, et al. The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol Biomarkers Prev 2003;12:114-9.
23. Bibbo M, Dytch HE, Alenghat E, Bartels PH, Wied GL. DNA ploidy profiles as prognostic indicators in CIN lesions. Am J Clin Pathol 1989;92:261-5. 10.1093/ajcp/92.3.261
24. Bleecker E, Koehler E, Smith J, Budwit D, Rahangdale L. Outcomes after management of young women with cervical intraepithelial neoplasia 2 with a 6-month observation protocol. J Low Genit Tract Dis 2014;18:46-9. 10.1097/LGT.0b013e3182901ef3
25. de Vet HC, Knipschild PG, Willebrand D, Schouten HJ, Sturmans F. The effect of beta-carotene on the regression and progression of cervical dysplasia: a clinical experiment. J Clin Epidemiol 1991;44:273-83. 10.1016/0895-4356(91)90039-C
26. Discacciati MG, de Souza CA, d'Otavianno MG, et al. Outcome of expectant management of cervical intraepithelial neoplasia grade in women followed for 12 months. Eur J Obstet Gynecol Reprod Biol 2011;155:204-810.1016/j.ejogrb.2010.12.002
27. Discacciati MG, da Silva IDCG, Villa LL, et al. Prognostic value of DNA and mRNA e6/e7 of human papillomavirus in the evolution of cervical intraepithelial neoplasia grade 2. Biomark Insights 2014;9:15-22. 10.4137/BMI.S14296
28. Loffredo D'Ottaviano MG, Discacciati MG, Andreoli MA, et al, HPV 16 Is Related to the Progression of Cervical Intraepithelial Neoplasia Grade 2: A Case Series. Obstet Gynecol Int 2013;2013:328909.
29. Fuchs K, Weitzen S, Wu L, Phipps MG, Boardman LA. Management of cervical intraepithelial neoplasia 2 in adolescent and young women. J Pediatr Adolesc Gynecol 2007;20:269-74. 10.1016/j. jpag.2007.04.012
30. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Biagini G, et al. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol Oncol 1996;61: 197-203. 10.1006/gyno.1996.0124
31. Guedes AC, Brenna SM, Coelho SA, Martinez EZ, Syrjänen KJ, Zeferino LC. p16(INK4a) Expression does not predict the outcome of cervical intraepithelial neoplasia grade 2. Int J Gynecol Cancer 2007;17:1099-103. 10.1111/j.1525-1438.2007.00899.x
32. Guedes AC, Zeferino LC, Syrjänen KJ, Brenna SM. Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis. Anticancer Res 2010;30:2319-23.
33. Hillemanns P, Garcia F, Petry KU, et al. A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. Am J Obstet Gynecol 2015;212:465. e1-7. 10.1016/j.ajog.2014.10.1107
34. Ho GY, Einstein MH, Romney SL, et al, Albert Einstein Cervix Dysplasia Clinical Consortium. Risk factors for persistent cervical intraepithelial neoplasia grades 1 and 2: managed by watchful waiting. J Low Genit Tract Dis 2011;15:268-75. 10.1097/ LGT.0b013e3182216fef
35. Hørding U, Daugaard S, Bock JE, Sebbelov AM, Norrild B. HPV 11, and 18 DNA sequences in cervical swabs from women with cervical dysplasia: prevalence and associated risk of progression. Eur J Obstet Gynecol Reprod Biol 1991;40:43-8. 10.1016/0028-2243(91)90043-K
36. Hosaka M, Fujita H, Hanley SJ, et al. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women. Int J Cancer 2013;132:327-34. 10.1002/ijc.27680
37. Iwasaka T, Matsuo N, Yokoyama M, Uchiyama M, Fukuda K, Sugimori H. Prospective follow-up of Japanese women with cervical intraepithelial neoplasia and various human papillomavirus types. Int J Gynaecol Obstet 1998;62:269-7710.1016/S0020-7292(98)00072-1.
38. Kataja V, Syrjänen S, Mäntyjärvi R, Yliskoski M, Saarikoski S, Syrjänen K. Prognostic factors in cervical human papillomavirus infections. Sex Transm Dis 1992;19:154-60. 10.1097/00007435-199205000-00009
39. Keefe KA, Schell MJ, Brewer C, et al. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2001;10:1029-35.
40. Kruse AJ, Baak JP, Janssen EA, et al. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol 2004;26:13-20.
41. Kruse AJ, Skaland I, Janssen EA, et al. Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol 2004;23:100-9. 10.1097/00004347-200404000-00003
42. Loopik DL, Doucette S, Bekkers RL, Bentley JR. Regression and Progression Predictors of CIN2 in Women Younger Than Years. J Low Genit Tract Dis 2016;20:213-7. 10.1097/ LGT.0000000000000215
43. Matsumoto K, Oki A, Furuta R, et al, Japan HPV And Cervical Cancer Study Group. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011;128:2898-910. 10.1002/ijc.25630
44. McAllum B, Sykes PH, Sadler L, Macnab H, Simcock BJ, Mekhail AK. Is the treatment of CIN 2 always necessary in women under 25 years old? Am J Obstet Gynecol 2011;205:478.e1-7. 10.1016/j. ajog.2011.06.069
45. Meyskens FLJr, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 1994;86:539-43. 10.1093/jnci/86.7.539
46. Miyamoto S, Hasegawa J, Morioka M, Hirota Y, Kushima M, Sekizawa A. The association between p16 and Ki-67 immunohistostaining and the progression of cervical intraepithelial neoplasia grade 2. Int J Gynaecol Obstet 2016;134:45-8. 10.1016/j. ijgo.2015.12.005
47. Mizushima T, Asai-Sato M, Akimoto K, et al. Aberrant Expression of the Cell Polarity Regulator aPKC/ is Associated With Disease Progression in Cervical Intraepithelial Neoplasia (CIN): A Possible Marker for Predicting CIN Prognosis. Int J Gynecol Pathol 2016;35:106-17. 10.1097/ PGP.0000000000000228
48. Monteiro DL, Trajano AJ, Russomano FB, Silva KS. Prognosis of intraepithelial cervical lesion during adolescence in up to two years of follow-up. J Pediatr Adolesc Gynecol 2010;23:230-6. 10.1016/j. jpag.2010.01.002
49. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 2007;197:141.e1-6. 10.1016/j. ajog.2007.03.029
50. Munk AC, \Ovestad IT, Gudlaugsson E, et al. Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study. Infect Agent Cancer 2012;7:30. 10.1186/1750-9378-7-30
51. Munk AC, Gudlaugsson E, Malpica A, et al. Consistent condom use increases the regression rate of cervical intraepithelial neoplasia 2-3[Electronic Resource]. PLoS One 2012;7:e45114. 10.1371/ journal.pone.0045114
52. Munk AC, Gudlaugsson E, Ovestad IT, et al. Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression. Gynecol Oncol 2012;127:489-94. 10.1016/j.ygyno.2012.09.010
53. Munro A, Powell RGA, A Cohen P, et al. Spontaneous regression of CIN2 in women aged 18-24 years: a retrospective study of a state-wide population in Western Australia. Acta Obstet Gynecol Scand 2016;95:291-8. 10.1111/aogs.12835
54. Nogawa T, Hiura M, Tanaka H, et al, Japan Gynecologic Oncology Group. Prospective evaluation of the Amplicor HPV test for predicting progression of cervical intraepithelial neoplasia 2. J Obstet Gynaecol Res 2013;39:1347-53. 10.1111/jog.12068
55. Okadome M, Saito T, Tanaka H, et al, Japanese Gynecologic Oncology Group (JGOG). Potential impact of combined high-and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2. J Obstet Gynaecol Res 2014;40:561-9. 10.1111/jog.12202
56. Omori M, Hashi A, Nakazawa K, et al. Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. Am J Clin Pathol 2007;128:208-17. 10.1309/0UP5PJK9RYF7BPHM
57. Rahangdale L, Lippmann QK, Garcia K, Budwit D, Smith JS, van Le L. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. Am J Obstet Gynecol 2014;210:314.e1-8. 10.1016/j.ajog.2013.12.042
58. Ueda Y, Enomoto T, Miyatake T, et al. Monoclonal expansion with integration of high-risk type human papillomaviruses is an initial step for cervical carcinogenesis: association of clonal status and human papillomavirus infection with clinical outcome in cervical intraepithelial neoplasia. Lab Invest 2003;83:1517-27. 10.1097/01.LAB.0000092234.68751.83
59. VAN Delft KWM, Mertens HJMM. Treatment strategies in intermediate cervical neoplasia: Implications of radical surgery. Oncol Lett 2011;2:575-8. 10.3892/ol.2011.289
60. Wang SM, Colombara D, Shi JF, et al. Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses. Int J Gynecol Cancer 2013;23:716-23. 10.1097/IGC.0b013e318286a95d
61. Weaver MG, Abdul-Karim FW, Dale G, Sorensen K, Huang YT. Outcome in mild and moderate cervical dysplasias related to the presence of specific human papillomavirus types. Mod Pathol 1990;3:679-83.
62. Woodman CB, Byrne P, Kelly KA, Hilton C. A randomized trial of laser vaporization in the management of cervical intraepithelial neoplasia associated with human papilloma virus infection. J Public Health Med 1993;15:327-31. 10.1093/oxfordjournals.pubmed.a042884
63. Yokoyama M, Iwasaka T, Nagata C, et al. Prognostic factors associated with the clinical outcome of cervical intraepithelial neoplasia: a cohort study in Japan. Cancer Lett 2003;192:171-9. 10.1016/ S0304-3835(02)00715-2
64. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007;26:441-6. 10.1097/ pgp.0b013e31805152ab
65. Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5. 10.1001/jama.285.11.1500
66. Ismail SM, Colclough AB, Dinnen JS, et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ 1989;298:707-10. 10.1136/bmj.298.6675.707
67. Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013;178:1161-9. 10.1093/aje/kwt077
68. van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:559-65. 10.1038/bjc.1991.350
69. Wilkinson TM, Sykes PHH, Simcock B, Petrich S. Recurrence of highgrade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2. Am J Obstet Gynecol 2015;212:769.e1-7. 10.1016/j.ajog.2015.01.010
70. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34. 10.1016/S1470-2045(08)70103-7
71. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35: 210-20. 10.1016/j.ctrv.2008.10.005
72. Waxman AG, Chelmow D, Darragh TM, Lawson H, Moscicki AB. Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol 2012;120:1465-71. 10.1097/ AOG.0b013e31827001d5
73. Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010;34:1077-87. 10.1097/ PAS.0b013e3181e8b2c4
74. Mirabello L, Schiffman M, Ghosh A, et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2013;132:1412-22. 10.1002/ijc.27750
75. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, et al. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer 2014;135:1425-32. 10.1002/ijc.28790
76. Louvanto K, Franco EL, Ramanakumar AV, et al, Biomarkers of Cervical Cancer Risk Study Team. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int J Cancer 2015;136:E638-45. 10.1002/ijc.29196
77. Kottaridi C, Kyrgiou M, Pouliakis A. Quantitative Measurement of L1 Human Papillomavirus Type 16 Methylation for the Prediction of Preinvasive and Invasive Cervical Disease. J Infect Dis 2017;215: 764-71. 10.1093/infdis/jiw645
78. Mitra A, MacIntyre DA, Lee YS. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep 2015;5:16865. 10.1038/srep16865